Clene Inc. (CLNN) Stock

Consumer Defensive · Packaged Foods · Member of Other US Stocks

Clene Inc. (CLNN) closed at USD 3.31 on 2026-10-14, a change of -64.7 % over the past year, with a market capitalization of USD 46.98M.

Clene Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Clene Inc. key figures

Previous close

USD 3.31 (2026-10-14)

1-year change

-64.7 %

Market cap

USD 46.98M

Enterprise value

USD 55.14M

P/E ratio (trailing)

-0.98

P/E ratio (forward)

-1.36

EPS (trailing)

-3.39

EPS (forward)

-2.44

PEG ratio

n/a

Price to book

-1.70

Revenue growth

233.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.15

Employees

76

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Clene Inc. and compare it with other stocks.